secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2021-08-23T23:59:59+00:00
Accession:  0001564590-21-045408
Event type: leadership
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Enanta Pharmaceuticals elects Yujiro S. Hata to board of directors
------------------------------------------------------------------

- Yujiro S. Hata elected as independent director, effective August 19, 2021.
- Board expanded to seven members; Hata appointed to Compensation and Nominating & Corporate Governance committees.
- Received non-statutory stock option for 13,144 shares vesting over 36 months.
- Will receive standard non-employee director cash compensation and indemnification agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000156459021045408/0001564590-21-045408-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000156459021045408/enta-8k_20210819.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-045408

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer